Skip to main content

Advertisement

  • Research
  • Open Access

The association between Alu hypomethylation and severity of type 2 diabetes mellitus

Clinical EpigeneticsThe official journal of the Clinical Epigenetics Society20179:93

https://doi.org/10.1186/s13148-017-0395-6

©  The Author(s). 2017

  • Received: 28 April 2017
  • Accepted: 24 August 2017
  • Published:

Abstract

Background

Cellular senescence due to genomic instability is believed to be one of the mechanisms causing health problems in diabetes mellitus (DM). Low methylation levels of Alu elements or Alu hypomethylation, an epigenomic event causing genomic instability, were commonly found in aging people and patients with aging phenotypes, such as osteoporosis.

Results

We investigate Alu methylation levels of white blood cells of type 2 DM, pre-DM, and control. The DM group possess the lowest Alu methylation (P < 0.001, P < 0.0001 adjusted age). In the DM group, Alu hypomethylation is directly correlated with high fasting blood sugar, HbA1C, and blood pressure.

Conclusion

Genome-wide hypomethylation may be one of the underlining mechanisms causing genomic instability in type 2 DM. Moreover, Alu methylation levels may be a useful biomarker for monitoring cellular senescence in type 2 DM patients.

Keywords

  • DNA methylation
  • Diabetes mellitus
  • Genomic instability
  • Alu
  • Senescence

Background

Diabetes mellitus or DM is a complex multifactorial disorder in which the person has high blood glucose (hyperglycemia) [1, 2]. Type 2 DM is the most common type of diabetes. At present, an estimated 387 million people have DM, and that number is expected to reach 592 million by 2035 [3]. DM patients possess increased risk of various geriatric conditions; therefore, type 2 DM is one of the most serious health problems in the world [4–7]. Cellular senescence, particularly vascular senescence, is believed to be a main contributing factor to DM-related complications, such as retinopathy, kidney failure, cerebrovascular disease, and delay wound healing [8, 9]. Nevertheless, the cellular senescence mechanism in DM remains to be explored.

A low Alu methylation level, Alu hypomethylation, has been reported to represent a cellular senescence biomarker [10, 11]. There are more than 1 million copies of Alu elements, a class of short intersperse elements [12]. Alu elements involve up to 11% of the human genome [13]. Alu hypomethylation was first found in white blood cells (WBCs) of aging people during ages 34–68 years [10, 14]. In contrast to aging, higher Alu methylation levels were found in individuals who had catch-up growth during newborn periods [15]. Alu hypomethylation may play a role in the senescence process. When age is adjusted, Alu hypomethylation is independently associated with lower bone mass density including osteopenia and osteoporosis and a high body mass index [11]. Therefore, it is interesting to explore whether cellular senescence of DM also correlates with Alu hypomethylation. Many studies concluded that genome-wide hypomethylation can promote genomic instability [16, 17]. This study will provide information about whether or not global hypomethylation promoting genomic instability is involved in DM pathogenesis.

To investigate Alu methylation changes during type 2 DM development, we measured the level of Alu methylation in normal, pre-type 2 DM, and type 2 DM patients by ALU-Combined Bisulfite Restriction Analysis. COBRA-interspersed repetitive sequence PCR is a highly accurate quantitative methylation measurement. Where pyrosequencing cannot demonstrate DNA methylation pattern, COBRA, detecting more than one CpG site, can (Additional file 1: Figure S1). In many cases, the DNA methylation pattern was more sensitive in revealing DNA methylation changes than DNA methylation levels alone [18–20].

Methods

Participants

For the study, we used 240 cases that were being monitored by fasting blood sugar (FBS) levels and were classified into three groups: normal (80 samples), pre-DM (80 samples), and DM (80 samples). Pre-DM and DM were admitted to the Tambon Health Promoting Hospital, Thailand, between 2015 and 2016. Sample ages were between 15 and 80 years. All subjects voluntarily participated in the study. The study was reviewed and approved by the Ethics Clearance Committee on Human Rights Related to Research Involving Human Subjects, Walailak University, Nakhon Si Thammarat, Thailand. Written informed consent was obtained from each participant.

DNA extraction and bisulfite DNA modification

DNA was extracted from buffy coat using proteinase K digestion and phenol-chloroform extraction protocols. Bisulfite treatment was performed as per standard protocols, with some modifications. Briefly, denatured genomic DNA was incubated in 0.22 M NaOH at 37 °C for 10 min, followed by addition of 30 μl of 10 mM hydroquinone and 520 μl of 3 M sodium-bisulfite for 16–20 h at 50 °C. Subsequently, the DNA was purified and incubated in 0.33 M NaOH at 25 °C for 3 min, ethanol precipitated, washed with 70% ethanol, and resuspended in 20 μl of H2O.

ALU-Combined Bisulfite Restriction Analysis (COBRA)

To observe methylation levels of Alu in samples, the sodium-bisulfite-treated DNA in each sample was amplified by PCR containing 1x PCR buffer (Qiagen, Germany), 0.2 mM of deoxynucleotide triphosphate (Promega, USA), 1 mM of magnesium chloride (Qiagen, Germany), 25 U of HotStarTaq DNA Polymerase (Qiagen, Germany), and 0.3 μM primer pairs: ALU-BRev (5′-CTAACTTTTTATATTTTTAATAAAAACRAAATTTCAC CA-3′) where R = A and G and Y = C and T. For Alu amplification, the program was set as follows: 95 °C for 15 min, 40 cycles of 95 °C for 45 s, 57 °C for 45 s, and 72 °C for 45 s, followed by a final extension of 72 °C for 7 min [20]. Alu PCR products were subjected to COBRA using 2 U of TaqI (Thermo scientific, USA), 2 U of TasI (Thermo scientific, USA), 5x NEB3 buffer (New England Biolabs, USA), and 1 μg/ul bovine serum albumin (BSA) (New England Biolabs, USA) and incubated at 65 °C overnight. The cut PCR products were analyzed by 8% acrylamide gel and SYBR stain (Lonza, USA). The band intensity of Alu methylation was observed and measured by typhoon fla 7000 and ImageQuanNT Software (Amersham biosciences, UK) (Additional file 1: Figure S1) [11].

Methylation analysis

ALU methylation analysis consisted of calculating the band intensity of the five Alu product sizes; 133, 90, 75, 58, and 43 bp according to the formula: A = 133/133, B = 58/58, C = 75/75, D = 90/90, E = 43/43, and F = [(E + B) − (C + D)]/2. The Alu methylation level was calculated from [(E + B) × 100]/(2A + E + B + C + D).

Statistical analyses

Data was analyzed with SPSS statistical software. The average and distributions of characteristic data of type 2 DM are presented as the mean ± SD and median. Pearson’s correlation between the Alu methylation pattern and characteristic data of the population were used to determine 95% confidence intervals of association. T-score was used to divide the subjects into three groups: normal, pre-DM, and DM. T-test was used to determine the differences using a P value threshold of 0.05 between the groups in the matched cases based on fasting blood sugar (FBS). Logistic regression models were used to evaluate the association between FBS by T-score as a dependent variable specified as a binary outcome, normal and DM and %mC, %mCmC loci, %uCmC loci, %mCuC loci, and %uCuC loci as independent predictors. All independent variables were used in the same model.

Results

Alu methylation in patients with type 2 diabetes

Fasting blood sugar (FBS) levels were used to classify the 240 samples into three groups: 80 normal controls, 80 pre-DM, and 80 type 2 DM. These samples were also classified using HbA1C levels resulting in several patients changing groups (42 normal, 113 pre-DM, and 85 DM) compared to the values from the FBS indicator (Table 1). Next, we used the ALU-Combined Bisulfite Restriction Analysis (COBRA-Alu) to measure Alu methylation in each sample. When comparing Alu methylation levels of the normal with the pre-DM and type 2 DM patients grouped according to FBS, we found that the level of Alu methylation was lowest in type 2 DM (P < 0.001) (Fig. 1a). Similarly, when grouped by the HbA1C indicator, we found significantly decreased Alu methylation levels in type 2 DM when compared with normal (P < 0.001) (Fig. 1b).
Table 1

Sample size, age, and body mass index (BMI) in each group by FBS and HbA1C indicator

 

Group

P value

Normal

Pre-DM

DM

FBS indicator

  n

80

80

80

 

 Sex

  Male

15 (18.75%)

12 (15.00%)

24 (30.00%)

 

  Female

65 (81.25%)

68 (85.00%)

56 (70.00%)

 

 Age (years) (mean ± SD)

50.04 ± 9.65

51.21 ± 9.27

59.99 ± 11.88

<0.001

 BMI (kg/m2) (mean ± SD)

25.04 ± 3.81

25.64 ± 3.97

27.17 ± 9.89

0.0984

HbA1C indicator

   n

42

113

85

 

 Sex

  Male

5 (11.90%)

28 (24.78%)

11 (12.94%)

 

  Female

37 (88.10%)

85 (75.22%)

74 (87.06%)

 

 Age (years) (mean ± SD)

47.67 ± 9.03

53.64 ± 10.67

56.89 ± 11.73

<0.001

 BMI (kg/m2) (mean ± SD)

23.82 ± 3.66

26.45 ± 7.94

26.31 ± 5.07

0.0627

Fig. 1
Fig. 1

The percentage of each Alu methylation level in normal, pre-DM, and DM samples grouped by fasting blood sugar level (a) and hemoglobin A1C (HbA1C) (b). Boxes represent interquartile ranges (25th to 75th percentile) and median lines represent the 50th percentile. The whiskers represent minimum and maximum values. *P < 0.05, **P < 0.001 (Mann-Whitney test)

Correlations between Alu methylation and FBS or HbA1C in normal, pre-DM, and type 2 DM are reported (Fig. 2 a–f). All groups showed higher biochemical markers of DM, FBS or HbA1C, and lower Alu methylation levels (Fig. 2 a–f). Moreover, the most striking comparison was the correlation between Alu methylation and HbA1C in DM (r 2 = −0.4705, P < 0.0001) (Fig. 2f).
Fig. 2
Fig. 2

Association between Alu methylation with FBS and HbA1C levels. Correlation between % Alu methylation and FBS in normal (a) pre-DM (b), and DM (c). Correlation between Alu methylation with HbA1C in normal (d), pre-DM (e), and DM (f). Pearson’s correlation coefficients (r) with P values are indicated (*P < 0.05, **P < 0.001)

Age- and sex-adjusted correlation

To determine if sex influenced Alu methylation levels, significant differences in Alu methylation levels were detected between males and females. Here, we divided males and females into normal, pre-DM, and type 2 DM groups. Alu methylation levels were not significantly different between males and females in either FBS (Fig. 3a) or HbA1C groups (Fig. 3b). This is consistent with previous works that have shown that sex does not affect Alu methylation [10, 15].
Fig. 3
Fig. 3

Comparisons of Alu methylation levels between male and female in normal, pre-DM, and DM when grouped using FBS indicator (a) and HbA1C indicator (b). The boxes represent interquartile ranges (25th to 75th percentile) and median lines represent the 50th percentile. The whiskers represent minimum and maximum values. *P < 0.05, **P < 0.001 (Mann-Whitney test)

The average age in normal and type 2 DM groups was not the same in our data (Table 1). To adjust for age difference, normal samples were matched to same-age DM samples to produce 30 age-matched pairs. The age-matched pairs showed significantly decreased Alu methylation in DM compared with normal in both the FBS (P < 0.001) and HbA1C groups (P < 0.001) (Fig. 4 a, b, respectively). Results were similar to findings before age adjustment (Fig. 1a, b).
Fig. 4
Fig. 4

The percentage of Alu methylation in age-matched pairs between normal samples and DM samples in both the FBS (a) and HbA1C groups (b). The values from 30 independent age-matched pairs are shown as box plots, with the boxes representing interquartile ranges (25th to 75th percentile) and median lines representing the 50th percentile. The whiskers represent minimum and maximum values. *P < 0.05, **P < 0.001 (Mann-Whitney test)

A significant negative correlation between Alu methylation and age was observed in all groups (normal, pre-DM, and DM) when using FBS (Fig. 5a–e) (r 2 = −0.2419, P = 0.0421, r 2 = −0.2336, P = 0.0431, and r 2 = −0.2807, P = 0.0313, respectively) and HbA1C (Fig. 5b–f) (r 2 = −0.3620, P = 0.0277, r 2 = −0.2055, P = 0.0392, and r 2 = −0.2320, P = 0.0019, respectively).
Fig. 5
Fig. 5

Correlation between Alu methylation and age in the FBS and HbA1C groups. Correlation between % Alu methylation and age in normal (a) pre-DM (b), and DM (c) for the FBS group. Association between Alu methylation with age grouped by HbA1C for normal (d), pre-DM (e), and DM (f). Each plot represents Alu methylation levels of sample. Pearson’s correlation coefficients (r) with P values are indicated (*P < 0.05, **P < 0.001)

Correlation between Alu methylation and hypertension in normal, pre-DM, and type 2 DM

Hypertension in type 2 DM is believed to be one of the severe consequences of vascular senescence [8, 21, 22]. We investigated the relationship between Alu methylation levels and blood pressure (systolic and diastolic) for FBS and HbA1C groups. The results showed a significantly negative association between Alu methylation and systolic pressure only in type 2 DM patients when classified by HbA1C (Fig. 6f). Intriguingly, a similar negative correlation between Alu methylation and diastolic pressure was observed in only type 2 DM patients for the HbA1C group (Fig. 7f). There was no significant correlation between Alu methylation and hypertension in normal or pre-DM samples in either the FBS (Figs. 6a, c and 7a, c) or HbA1C groups (Figs. 6b, d and 7b, d).
Fig. 6
Fig. 6

Relationship between Alu methylation and systolic pressure for normal (a) pre-DM (b), and DM (c) samples grouped by FBS. Alu methylation and systolic pressure for normal (d), pre-DM (e), and DM (f) samples grouped by HbA1C. Pearson’s correlation coefficients (r) with P values are indicated (**P < 0.001)

Fig. 7
Fig. 7

Association between Alu methylation and diastolic pressure for normal (a), pre-DM (b), and DM (c) samples grouped by FBS. Alu methylation and diastolic pressure for normal (d), pre-DM (e), and DM (f) samples grouped by HbA1C. Pearson’s correlation coefficients (r) with P values are indicated (**P < 0.001)

To prove that the correlation between Alu hypomethylation and hypertension was not influenced by age, we performed age-adjusted experiments (Fig. 8 a, b). Interestingly, the significant correlation was revealed in the DM using HbA1C as indicator (P = 0.0312) (Fig. 8a).
Fig. 8
Fig. 8

The percentage of Alu methylation levels in type 2 DM between high systolic/diastolic and normal to adjusted for age when grouped using FBS indicator (a) and HbA1C indicator (b). The boxes represent interquartile ranges (25th to 75th percentile) and median lines represent the 50th percentile. The whiskers represent minimum and maximum values. *P < 0.05, **P < 0.001 (Mann-Whitney test)

Discussion

Cellular dysfunction due to aging process was proposed to be one of the pathogenic mechanisms of type 2 DM [8, 9]. One known mechanism of cellular aging is decrement of genome-wide methylation-promoting genomic instability [17, 23]. Therefore, in this study, we proved that Alu methylation in type 2 DM patients was lower than that in the general population. Although we found significant differences between DM phenotype and Alu methylation level, there is a significant overlap between Alu methylation levels of DM cases and controls. Moreover, there is no significant difference between pre-DM and normal controls. These limit the use of using Alu methylation levels directly as a biomarker for clinical application. Further study should be performed to evaluate how the change of Alu methylation level of each individual is correlated with progression of the diseases.

Interestingly, we demonstrated a direct correlation between Alu hypomethylation levels with high blood pressure in DM samples when grouped by HbA1C. This association is similar to the correlation between Alu hypomethylation and lower bone mass [11]. Moreover, the fact that the correlation was found only when grouping DM by HbA1C reflected that the finding was a permanent change. Target cellular defects causing high blood pressure in DM are not WBC. The underlining reason of how Alu hypomethylation in WBC is associated with high blood pressure may be that the mechanism causing Alu hypomethylation in DM is systemic and methylation levels of other tissues remained to be explored. Nevertheless, the fact that Alu hypomethylation in WBC is associated with several geriatric degenerative diseases suggests that Alu hypomethylation levels in white blood cells are a promising biomarker for senescence monitoring.

Mechanisms of aberrant methylation and genomic instability in cellular senescence and type 2 DM are unclear. It is possible that oxidative stress products increase glutathione levels that could influence epigenetic processes including DNA and histone methylation by limiting the availability of S-adenosylmethionine (SAM) leading to DNA hypomethylation [24–26]. Alternatively, the common oxygen radical adduct 8-hydroxyguanine in DNA can dramatically inhibit the process of DNA methylation, so free radical damage may explain the decreased Alu methylation [27–30]. Possibly, high glucose concentration-induced cytosolic Ca2+ and ERK1/2 activation increases mitochondrial fragmentation and reactive oxygen species (ROS) levels [31–33]. Hence, hyperglycemia could promote cellular senescent formation by metabolic changes and tissue damage from oxidative stress resulting in increased free radicals that could lead to genomic hypomethylation and genomic instability in type 2 DM [34].

Conclusions

Our results not only showed significant Alu hypomethylation levels in type 2 DM but also its association with high blood pressure. Therefore, Alu methylation is a promising biomarker for monitoring type 2 DM complications. Moreover, Alu elements should be considered as epigenome-editing targets for future research in DM disability prevention and treatment.

Abbreviations

COBRA: 

Combined Bisulfite Restriction Analysis

DM: 

Diabetes mellitus

FBS: 

Fasting blood sugar

HbA1C: 

Hemoglobin A1c

ROS: 

Reactive oxygen species

SAM: 

S-adenosylmethionine

WBCs: 

White blood cells

Declarations

Acknowledgements

We thank the staff of the Ban Ton Riang Tambon Health Promoting Hospital, Nakhon Si Thammarat, Thailand, for their assistance in sample collection.

Funding

This study was financially supported by the Institute of Research and Development Walailak University Grant No. WU58310 and Thailand Research Fund (TRF) Grant No. MRG5980090. This work was supported by the Thailand Research Fund Grant No. DPG5980005.

Availability of data and materials

Not application.

Authors’ contributions

JT isolated DNA from plasma samples and processed the data. JT and MP performed the bisulfite DNA modification. JT and AM wrote the first draft of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was reviewed and approved by the Ethics Clearance Committee on Human Rights Related to Researched Involving Human Subjects, Walailak University, Nakhon Si Thammarat, Thailand. Written informed consent was obtained from each participant.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
School of Medicine, Walailak University, Nakhon Si Thammarat, Thailand
(2)
Inter-Department Program of Biomedical Sciences, Faculty of Graduate School, Chulalongkorn University, Bangkok, Thailand
(3)
Center for Excellence in Molecular Genetics of Cancer and Human Diseases, Chulalongkorn University, Bangkok, Thailand
(4)
Department of Anatomy, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

References

  1. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James WPT, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.View ArticlePubMedGoogle Scholar
  2. Wang G. Raison d’être of insulin resistance: the adjustable threshold hypothesis. J R Soc Interface. 2014;11(101):20140892.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Peer N, Kengne A-P, Motala AA, Mbanya JC. Diabetes in the Africa Region: an update. Diabetes Res Clin Pract. 2014;103(2):197–205.View ArticlePubMedGoogle Scholar
  4. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: worthless or valuable? Diabetes Care. 2013;36(Supplement 2):S120–6.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.View ArticlePubMedPubMed CentralGoogle Scholar
  6. Leong A, Porneala B, Dupuis J, Florez JC, Meigs JB. Type 2 diabetes genetic predisposition, obesity, and all-cause mortality risk in the US: a multiethnic analysis. Diabetes Care. 2016;39(4):539–46.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Fuchsberger C, Flannick J, Teslovich TM, Mahajan A, Agarwala V, Gaulton KJ, Ma C, Fontanillas P, Moutsianas L, McCarthy DJ. The genetic architecture of type 2 diabetes. Nature. 2016;536(7614):41–47. Google Scholar
  8. Palmer AK, Tchkonia T, LeBrasseur NK, Chini EN, Xu M, Kirkland JL. Cellular senescence in type 2 diabetes: a therapeutic opportunity. Diabetes. 2015;64(7):2289–98.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Testa R, Ceriello A. Pathogenetic loop between diabetes and cell senescence. Diabetes Care. 2007;30(11):2974–5.View ArticlePubMedGoogle Scholar
  10. Jintaridth P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. Physiol Genomics. 2010;41(2):194–200.View ArticlePubMedGoogle Scholar
  11. Jintaridth P, Tungtrongchitr R, Preutthipan S, Mutirangura A. Hypomethylation of Alu elements in post-menopausal women with osteoporosis. PloS one. 2013;8(8):1–8.Google Scholar
  12. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet. 2002;3(5):370–9.View ArticlePubMedGoogle Scholar
  13. Deininger PL, Moran JV, Batzer MA, Kazazian HH. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev. 2003;13(6):651–8.View ArticlePubMedGoogle Scholar
  14. Terry MB, Delgado-Cruzata L, Vin-Raviv N, Wu HC, Santella RM. DNA methylation in white blood cells: association with risk factors in epidemiologic studies. Epigenetics. 2011;6(7):828–37.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Rerkasem K, Rattanatanyong P, Rerkasem A, Wongthanee A, Rungruengthanakit K, Mangklabruks A, Mutirangura A. Higher Alu methylation levels in catch-up growth in twenty-year-old offsprings. PLoS One. 2015;10(3):e0120032.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Jung M, Pfeifer GP. Aging and DNA methylation. BMC Biol. 2015;13(1):7.View ArticlePubMedPubMed CentralGoogle Scholar
  17. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Pobsook T, Subbalekha K, Sannikorn P, Mutirangura A. Improved measurement of LINE-1 sequence methylation for cancer detection. Clin Chim Acta. 2011;412(3):314–21.View ArticlePubMedGoogle Scholar
  19. Wangsri S, Subbalekha K, Kitkumthorn N, Mutirangura A. Patterns and possible roles of LINE-1 methylation changes in smoke-exposed epithelia. PLoS One. 2012;7(9):e45292.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Nakkuntod J, Sukkapan P, Avihingsanon Y, Mutirangura A, Hirankarn N. DNA methylation of human endogenous retrovirus in systemic lupus erythematosus. J Hum Genet. 2013;58(5):241–9.View ArticlePubMedGoogle Scholar
  21. Harvey A, Montezano AC, Touyz RM. Vascular biology of ageing—implications in hypertension. J Mol Cell Cardiol. 2015;83:112–21.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Minamino T, Komuro I. Vascular cell senescence. Circ Res. 2007;100(1):15–26.View ArticlePubMedGoogle Scholar
  23. Benayoun BA, Pollina EA, Brunet A. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat Rev Mol Cell Biol. 2015;16(10):593–610.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Kloypan C, Srisa-art M, Mutirangura A, Boonla C. LINE-1 hypomethylation induced by reactive oxygen species is mediated via depletion of S-adenosylmethionine. Cell Biochem Funct. 2015;33(6):375–84.View ArticlePubMedGoogle Scholar
  25. Anier K, Zharkovsky A, Kalda A. S-adenosylmethionine modifies cocaine-induced DNA methylation and increases locomotor sensitization in mice. Int J Neuropsychopharmacol. 2013;16(9):2053–66.View ArticlePubMedGoogle Scholar
  26. Gören JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy. 2004;24(11):1501–7.View ArticlePubMedGoogle Scholar
  27. Shi Y, Hu FB. The global implications of diabetes and cancer. Lancet. 2014;383(9933):1947–8.View ArticlePubMedGoogle Scholar
  28. Weitzman SA, Turk PW, Milkowski DH, Kozlowski K. Free radical adducts induce alterations in DNA cytosine methylation. Proc Natl Acad Sci. 1994;91(4):1261–4.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Turk PW, Laayoun A, Smith SS, Weitzman SA. DNA adduct 8-hydroxyl-2′-deoxyguanosine (8-hydroxyguanine) affects function of human DNA methyltransferase. Carcinogenesis. 1995;16(5):1253–5.View ArticlePubMedGoogle Scholar
  30. Tucker KL. Methylated cytosine and the brain: a new base for neuroscience. Neuron. 2001;30(3):649–52.View ArticlePubMedGoogle Scholar
  31. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci U S A. 2006;103(8):2653–8.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117(5):1219–22.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Shah GN, Morofuji Y, Banks WA, Price TO. High glucose-induced mitochondrial respiration and reactive oxygen species in mouse cerebral pericytes is reversed by pharmacological inhibition of mitochondrial carbonic anhydrases: implications for cerebral microvascular disease in diabetes. Biochem Biophys Res Commun. 2013;440(2):354–8.View ArticlePubMedGoogle Scholar
  34. Attia S, Helal G, Alhaider A. Assessment of genomic instability in normal and diabetic rats treated with metformin. Chem Biol Interact. 2009;180(2):296–304.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement

Clinical Epigenetics

ISSN: 1868-7083

Contact us